Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate

OBJECTIVES: U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without methotrexate (MTX), were more effective than a strateg...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Rheumatology (Oxford)
Glavni autori: Verhoeven, Maxime M A, Tekstra, Janneke, Welsing, Paco M J, Pethö-Schramm, Attila, Borm, Michelle E A, Bruyn, George A W, Bos, Reinhard, Griep, Ed N, Klaasen, Ruth, van Laar, Jacob M, Lafeber, Floris P J G, Bijlsma, Johannes W J, de Hair, Marjolein J H, Jacobs, Johannes W G
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Science
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449801/
https://ncbi.nlm.nih.gov/pubmed/31859346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kez602
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items